Introducing StartReta
A once-weekly triple-hormone receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly. In trials, patients lost up to 24% of their body weight in 48 weeks — the largest reduction ever recorded for a pharmaceutical.
A personal message
👋
Retatrutide is an investigational injectable medication that targets three metabolic hormone pathways at once. Where Ozempic hits one receptor and Mounjaro hits two, retatrutide hits three — translating to dramatically greater weight loss and metabolic benefit in clinical trials.
Phase 2 results published in the New England Journal of Medicine showed average weight reductions of 24.2% at the highest dose — outperforming every other obesity drug on the market today.
Peak annual revenue projected by Wall Street analysts
Adults globally who could be eligible for treatment
Average body weight lost at the highest trial dose
If approved on its expected timeline, retatrutide is forecast to eclipse Humira, Keytruda, and even Ozempic to become the highest-grossing pharmaceutical product ever sold — reshaping the global treatment of obesity, diabetes, and cardiometabolic disease.
Join the StartReta waitlist and we'll connect you with a licensed provider the moment retatrutide becomes available.